84 related articles for article (PubMed ID: 25275023)
1. New therapeutic possibilities of combined treatment of radiotherapy with oxaliplatin and its liposomal formulation, Lipoxal™, in rectal cancer using xenograft in nude mice.
Tippayamontri T; Kotb R; Sanche L; Paquette B
Anticancer Res; 2014 Oct; 34(10):5303-12. PubMed ID: 25275023
[TBL] [Abstract][Full Text] [Related]
2. Efficacy of cisplatin and Lipoplatin™ in combined treatment with radiation of a colorectal tumor in nude mouse.
Tippayamontri T; Kotb R; Paquette B; Sanche L
Anticancer Res; 2013 Aug; 33(8):3005-14. PubMed ID: 23898053
[TBL] [Abstract][Full Text] [Related]
3. Synergism in concomitant chemoradiotherapy of cisplatin and oxaliplatin and their liposomal formulation in the human colorectal cancer HCT116 model.
Tippayamontri T; Kotb R; Paquette B; Sanche L
Anticancer Res; 2012 Oct; 32(10):4395-404. PubMed ID: 23060564
[TBL] [Abstract][Full Text] [Related]
4. Convection-enhancement delivery of liposomal formulation of oxaliplatin shows less toxicity than oxaliplatin yet maintains a similar median survival time in F98 glioma-bearing rat model.
Shi M; Fortin D; Paquette B; Sanche L
Invest New Drugs; 2016 Jun; 34(3):269-76. PubMed ID: 26961906
[TBL] [Abstract][Full Text] [Related]
5. Cellular uptake and cytoplasm / DNA distribution of cisplatin and oxaliplatin and their liposomal formulation in human colorectal cancer cell HCT116.
Tippayamontri T; Kotb R; Paquette B; Sanche L
Invest New Drugs; 2011 Dec; 29(6):1321-7. PubMed ID: 20658169
[TBL] [Abstract][Full Text] [Related]
6. PEG-liposomal oxaliplatin potentialization of antitumor efficiency in a nude mouse tumor-xenograft model of colorectal carcinoma.
Yang C; Liu HZ; Lu WD; Fu ZX
Oncol Rep; 2011 Jun; 25(6):1621-8. PubMed ID: 21455585
[TBL] [Abstract][Full Text] [Related]
7. Optimization of the route of platinum drugs administration to optimize the concomitant treatment with radiotherapy for glioblastoma implanted in the Fischer rat brain.
Charest G; Sanche L; Fortin D; Mathieu D; Paquette B
J Neurooncol; 2013 Dec; 115(3):365-73. PubMed ID: 24026531
[TBL] [Abstract][Full Text] [Related]
8. Preclinical efficacy and pharmacokinetics of AP5346, a novel diaminocyclohexane-platinum tumor-targeting drug delivery system.
Rice JR; Gerberich JL; Nowotnik DP; Howell SB
Clin Cancer Res; 2006 Apr; 12(7 Pt 1):2248-54. PubMed ID: 16609041
[TBL] [Abstract][Full Text] [Related]
9. Tumors established with cell lines selected for oxaliplatin resistance respond to oxaliplatin if combined with cetuximab.
Prewett M; Deevi DS; Bassi R; Fan F; Ellis LM; Hicklin DJ; Tonra JR
Clin Cancer Res; 2007 Dec; 13(24):7432-40. PubMed ID: 18094427
[TBL] [Abstract][Full Text] [Related]
10. Evaluation of capecitabine and oxaliplatin administered prior to and then concomitant to radiotherapy in high risk locally advanced rectal cancer.
Gao YH; An X; Sun WJ; Cai J; Cai MY; Kong LH; Lin JZ; Liu GC; Tang JH; Wu XJ; Chen G; Pan ZZ; Ding PR
J Surg Oncol; 2014 Apr; 109(5):478-82. PubMed ID: 24288203
[TBL] [Abstract][Full Text] [Related]
11. Concomitant Chemoradiation Therapy with Gold Nanoparticles and Platinum Drugs Co-Encapsulated in Liposomes.
Charest G; Tippayamontri T; Shi M; Wehbe M; Anantha M; Bally M; Sanche L
Int J Mol Sci; 2020 Jul; 21(14):. PubMed ID: 32659905
[TBL] [Abstract][Full Text] [Related]
12. Multiple administration of PEG-coated liposomal oxaliplatin enhances its therapeutic efficacy: a possible mechanism and the potential for clinical application.
Abu Lila AS; Eldin NE; Ichihara M; Ishida T; Kiwada H
Int J Pharm; 2012 Nov; 438(1-2):176-83. PubMed ID: 22944302
[TBL] [Abstract][Full Text] [Related]
13. In vivo and in vitro antitumor activity of oxaliplatin in combination with cetuximab in human colorectal tumor cell lines expressing different level of EGFR.
Balin-Gauthier D; Delord JP; Rochaix P; Mallard V; Thomas F; Hennebelle I; Bugat R; Canal P; Allal C
Cancer Chemother Pharmacol; 2006 Jun; 57(6):709-18. PubMed ID: 16320055
[TBL] [Abstract][Full Text] [Related]
14. Chemoradiation with raltitrexed and oxaliplatin in preoperative treatment of stage II-III resectable rectal cancer: Phase I and II studies.
Gambacorta MA; Valentini V; Coco C; Morganti AG; Smaniotto D; Miccichè F; Mantini G; Barbaro B; Garcia-Vargas JE; Magistrelli P; Picciocchi A; Cellini N
Int J Radiat Oncol Biol Phys; 2004 Sep; 60(1):139-48. PubMed ID: 15337549
[TBL] [Abstract][Full Text] [Related]
15. High-LET radiation combined with oxaliplatin induce autophagy in U-87 glioblastoma cells.
Benzina S; Altmeyer A; Malek F; Dufour P; Denis JM; Gueulette J; Bischoff P
Cancer Lett; 2008 Jun; 264(1):63-70. PubMed ID: 18329790
[TBL] [Abstract][Full Text] [Related]
16. Preoperative chemoradiotherapy and postoperative chemotherapy with fluorouracil and oxaliplatin versus fluorouracil alone in locally advanced rectal cancer: initial results of the German CAO/ARO/AIO-04 randomised phase 3 trial.
Rödel C; Liersch T; Becker H; Fietkau R; Hohenberger W; Hothorn T; Graeven U; Arnold D; Lang-Welzenbach M; Raab HR; Sülberg H; Wittekind C; Potapov S; Staib L; Hess C; Weigang-Köhler K; Grabenbauer GG; Hoffmanns H; Lindemann F; Schlenska-Lange A; Folprecht G; Sauer R;
Lancet Oncol; 2012 Jul; 13(7):679-87. PubMed ID: 22627104
[TBL] [Abstract][Full Text] [Related]
17. Correlation of pharmacokinetics with the antitumor activity of Cetuximab in nude mice bearing the GEO human colon carcinoma xenograft.
Luo FR; Yang Z; Dong H; Camuso A; McGlinchey K; Fager K; Flefleh C; Kan D; Inigo I; Castaneda S; Rose WC; Kramer RA; Wild R; Lee FY
Cancer Chemother Pharmacol; 2005 Nov; 56(5):455-64. PubMed ID: 15947929
[TBL] [Abstract][Full Text] [Related]
18. The enhancement of tumor radioresponse by combined treatment with cepharanthine is accompanied by the inhibition of DNA damage repair and the induction of apoptosis in oral squamous cell carcinoma.
Harada T; Harada K; Ueyama Y
Int J Oncol; 2012 Aug; 41(2):565-72. PubMed ID: 22664937
[TBL] [Abstract][Full Text] [Related]
19. Neoadjuvant capecitabine and oxaliplatin followed by synchronous chemoradiation and total mesorectal excision in magnetic resonance imaging-defined poor-risk rectal cancer.
Chau I; Brown G; Cunningham D; Tait D; Wotherspoon A; Norman AR; Tebbutt N; Hill M; Ross PJ; Massey A; Oates J
J Clin Oncol; 2006 Feb; 24(4):668-74. PubMed ID: 16446339
[TBL] [Abstract][Full Text] [Related]
20. Randomized, multicenter, phase IIb study of preoperative chemoradiotherapy in T3 mid-distal rectal cancer: raltitrexed + oxaliplatin + radiotherapy versus cisplatin + 5-fluorouracil + radiotherapy.
Valentini V; Coco C; Minsky BD; Gambacorta MA; Cosimelli M; Bellavita R; Morganti AG; La Torre G; Trodella L; Genovesi D; Portaluri M; Maurizi-Enrici R; Barbera F; Maranzano E; Lupattelli M
Int J Radiat Oncol Biol Phys; 2008 Feb; 70(2):403-12. PubMed ID: 17919844
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
